Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Non-Current Assets (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Non-Current Assets for 13 consecutive years, with $257.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets rose 25.77% year-over-year to $257.7 million, compared with a TTM value of $1.0 billion through Sep 2025, up 24.52%, and an annual FY2024 reading of $243.2 million, up 18.81% over the prior year.
  • Non-Current Assets was $257.7 million for Q3 2025 at Tandem Diabetes Care, down from $260.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $260.9 million in Q2 2025 and bottomed at $92.6 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $189.1 million, with a median of $202.8 million recorded in 2022.
  • The sharpest move saw Non-Current Assets surged 123.66% in 2022, then dropped 14.75% in 2023.
  • Year by year, Non-Current Assets stood at $93.6 million in 2021, then skyrocketed by 116.64% to $202.8 million in 2022, then rose by 0.92% to $204.7 million in 2023, then grew by 18.81% to $243.2 million in 2024, then increased by 5.98% to $257.7 million in 2025.
  • Business Quant data shows Non-Current Assets for TNDM at $257.7 million in Q3 2025, $260.9 million in Q2 2025, and $258.7 million in Q1 2025.